Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Class A Ordinary Shares, par value $0.0001 per share
-
Shares outstanding
-
63.5M
-
Number of holders
-
24
-
Total 13F shares, excl. options
-
36.9M
-
Shares change
-
+402K
-
Total reported value, excl. options
-
$291M
-
Value change
-
+$3.21M
-
Number of buys
-
9
-
Number of sells
-
-10
-
Price
-
$7.76
Significant Holders of MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) as of Q3 2022
26 filings reported holding MLTX - MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share as of Q3 2022.
MoonLake Immunotherapeutics - Class A Ordinary Shares, par value $0.0001 per share (MLTX) has 24 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36.9M shares
of 63.5M outstanding shares and own 58.05% of the company stock.
Largest 10 shareholders include BVF INC/IL (21.8M shares), Cormorant Asset Management, LP (6.07M shares), CITADEL ADVISORS LLC (2.69M shares), TCG Crossover Management, LLC (1M shares), PRICE T ROWE ASSOCIATES INC /MD/ (869K shares), FMR LLC (819K shares), BlackRock Inc. (742K shares), RTW INVESTMENTS, LP (500K shares), GREAT POINT PARTNERS LLC (492K shares), and Point72 Asset Management, L.P. (335K shares).
This table shows the top 24 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.